Johnson & Johnson Acquires Firefly Bio for $1 Billion
Johnson & Johnson agreed to acquire Firefly Bio, Inc., for $1 billion in cash to expand its cancer drug pipeline. The acquisition targets tumors driven by the KRAS gene mutation using Firefly's innovative protein-degrading platform technology.
Tickers: $JNJ